Cipla arm to acquire remaining 40 pc stake in Cipla Pharma Lanka for over Rs 1.5 lakh

Published On 2019-11-28 08:41 GMT   |   Update On 2019-11-28 08:41 GMT

The acquisition of 40 per cent stake is for a cash consideration of LKR 400,000 (over Rs 1.5 lakh) to be paid on closing of the transaction, Cipla said.


New Delhi: Pharma major Cipla on Wednesday said its arm Cipla (EU) Ltd has signed an agreement with CitiHealth Imports to acquire remaining 40 per cent stake in Cipla Pharma Lanka.


Cipla (EU) Ltd already has a 60 per cent stake in Cipla Pharma Lanka Pvt Ltd. Post-acquisition, Cipla Pharma Lanka will become a wholly-owned subsidiary, Cipla said in a filing to the BSE.


The acquisition of 40 per cent stake is for a cash consideration of LKR 400,000 (over Rs 1.5 lakh) to be paid on closing of the transaction, it added.


"The transaction is expected to be completed before December 10, 2019," the filing said.


Read Also: Cipla gets 4 USFDA observations for Patalganga facility


Cipla Pharma Lanka is a private limited liability company incorporated in Sri Lanka on August 8 2014 having a market share of 6.5 per cent in the Sri Lankan market, it added.


The company was formed as a joint venture between Cipla (EU) and CitiHealth Imports Pvt Ltd to conduct marketing and distribution of pharmaceutical products, Cipla said.


Read Also: Cipla acquires novel anti-infective Elores to further antimicrobial stewardship in critical care in India

Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News